Brainstorm Cell Therapeutics (NASDAQ:BCLI) announced its earnings results on Tuesday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.12), Bloomberg Earnings reports.

Shares of NASDAQ BCLI traded down $0.06 during midday trading on Wednesday, reaching $3.71. 229 shares of the company’s stock were exchanged, compared to its average volume of 91,868. Brainstorm Cell Therapeutics has a 52-week low of $2.92 and a 52-week high of $4.50. The company has a debt-to-equity ratio of 9.34, a quick ratio of 0.97 and a current ratio of 0.97. The stock’s fifty day moving average price is $3.99.

Several hedge funds and other institutional investors have recently made changes to their positions in BCLI. Delek Group Ltd. bought a new stake in Brainstorm Cell Therapeutics in the first quarter valued at about $183,000. CIBC Private Wealth Group LLC increased its holdings in Brainstorm Cell Therapeutics by 349.9% in the first quarter. CIBC Private Wealth Group LLC now owns 67,484 shares of the biotechnology company’s stock valued at $293,000 after buying an additional 52,484 shares during the last quarter. BlackRock Inc. increased its holdings in Brainstorm Cell Therapeutics by 44.6% in the second quarter. BlackRock Inc. now owns 130,281 shares of the biotechnology company’s stock valued at $514,000 after buying an additional 40,197 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Brainstorm Cell Therapeutics by 10.7% in the second quarter. Renaissance Technologies LLC now owns 224,377 shares of the biotechnology company’s stock valued at $886,000 after buying an additional 21,720 shares during the last quarter. 10.71% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have recently issued reports on the company. ValuEngine lowered Brainstorm Cell Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 3rd. Maxim Group reaffirmed a “buy” rating and set a $9.00 target price on shares of Brainstorm Cell Therapeutics in a research report on Tuesday, May 14th.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.

Recommended Story: Insider Trading – What You Need to Know

Earnings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.